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Abstract 
Background: Paraoxonase 1 (PON1) gene polymorphisms and polyphenols intake have been reported indepen-
dently associated to lipid profile and susceptibility to atherosclerosis and cardiovascular disease. However, the interac-
tion between these factors remains to be investigated. We performed an observational nutrigenetic study to examine 
whether the interaction between polyphenols and anthocyanins intake and PON1 genetic variants can modulate 
biomarkers of cardiovascular health in an Italian healthy population.
Methods: We recruited 443 healthy volunteers who participated in the EC funded ATHENA project (AnThocyanin and 
polyphenols bioactive for Health Enhancement through Nutritional Advancement). Data collection included detailed 
demographic, clinical, dietary, lifestyle, biochemical and genetic data. Polyphenols and anthocyanins intake was 
measured by 24 h dietary recall repeated three times a year in order to get seasonal variations. We tested the interac-
tion between 18 independent tagging SNPs in PON1 gene and polyphenols intake on HDL, LDL, cholesterol, triglycer-
ides and atherogenic index of plasma.
Results: Without considering the genetic background, we could not observe significant differences in the lipid 
profile between high and low polyphenols and anthocyanins intake. Using a nutrigenetic approach, we identified 
protective genotypes in four independent polymorphisms that, at Bonferroni level (p ≤ 0.0028), present a significant 
association with increased HDL level under high polyphenols and anthocyanins intake, compared to risk genotypes 
(rs854549, Beta = 4.7 per C allele; rs854552, Beta = 5.6 per C allele; rs854571, Beta = 3.92 per T allele; rs854572, 
Beta = 3.94 per C allele).
Conclusions: We highlight the protective role of genetic variants in PON1 towards cardiovascular risk under high 
polyphenols and anthocyanins consumption. PON1 variants could represent novel biomarkers to stratify individu-
als who might benefit from targeted dietary recommendation for health promotion and strategies of preventive 
medicine.
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Background
Cardiovascular disease (CVD) is responsible of approxi-
mately one-third of deaths in the world and its risk fac-
tors continue to increase [1, 2]. Since 2007, the ‘Grand 
challenges in chronic non-communicable diseases’ out-
lined that promoting salutary lifestyle and increasing the 
availability and consumption of healthy food have a key 
role in the protection against chronic diseases, a global 
epidemic and economic burden for our society [3, 4].
The physiological response to diet can be modulated 
by the genetic background, with common DNA variants 
having the potential to affect specific functional pathways 
and making subjects more or less responder to a specific 
diet [5]. For instance, changes in plasma lipid concentra-
tion in response to dietary fat intake are largely geneti-
cally controlled [6, 7].
Epidemiological studies support the preventive effect of 
anthocyanins and polyphenols towards the onset of CVD 
[8–11] through their great antioxidant and antiathero-
sclerotic activity [12, 13]. Animal and in vitro studies are 
in favor of their potential to influence lipid profile, a com-
monly used biomarker of cardiovascular risk [13]. They 
can slow or inhibit the absorption of lipids and glucose in 
the intestine and inhibit cholesterol synthesis [14], which 
results in a decrease in serum triglyceride, total choles-
terol and non-HDL cholesterol and in increase in serum 
HDL. Moreover, they promote reverse cholesterol trans-
port, which also contributes to their effect on lipid profile 
[12, 15, 16].
Polyphenols are the most abundant antioxidants in the 
diet. Their dietary intake can be as high as 1 g/dl, much 
higher than that of all other known dietary antioxidants. 
Their main dietary sources are fruits and plant-derived 
beverages (fruit juices, tea, coffee and red wine), vegeta-
bles, cereals, chocolate and dry legumes.
Anthocyanins are plant pigments members of the fla-
vonoid family of polyphenols, providing the bright red–
orange to blue–violet colors present in many fruits and 
vegetables.
Interventional studies have consistently reported that 
polyphenols and athocyanins-rich diets can modulate 
paraoxonase 1 (PON1) activity and/or the level of PON1 
expression [17–19]. PON1 is a member of a gene fam-
ily, which also comprises PON2 and PON3, all clustered 
in tandem on the long arm of human chromosome 7 
(q21.22). PON1 enzyme is a glycoprotein with hydrolytic 
activity [20], which associates with HDL in the circula-
tion. It metabolizes a broad variety of substrates, and is a 
primary determinant of the antioxidant and anti-inflam-
matory activity of HDL, promoting the HDL-mediated 
macrophage cholesterol efflux [15, 16]. As such, PON1 
plays a relevant role in determining susceptibility to ath-
erosclerosis and cardiovascular disease [17, 21, 22]. It is 
recognized that PON1 activity is genetically regulated, 
with Single Nucleotide Polymorphisms (SNPs) exhibit-
ing strong association with its arylesterase and paraoxa-
nase activities [17, 20, 23]. By the way, the wide range of 
serum PON1 activity among individuals is only partially 
explained by genetic polymorphisms. The presence of 
additional factors known to modulate PON1 activity and 
HDL (e.g. dietary factors, lifestyle, statins, etc.) also needs 
to be taken into account.
The EC funded the Athena project (FP7-KBBE-2009-3) 
“Anthocyanin and polyphenols bioactive for health 
enhancement through nutritional advancement”. Within 
this project, we conducted an observational study with 
the aim to explore the relationship between SNPs in 
PON1 and lipid profile as biomarker of cardiovascular 
health, taking into consideration polyphenols and antho-
cyanins consumption. We selected HDL, LDL, total cho-
lesterol, triglycerides and the atherogenic index of plasma 
(AIP) as common biomarkers, broadly used in clinical 
practice and with limited inter- and intra assay variability.
Methods
Study design and participants
We performed an observational nutrigenetic study on 
500 volunteers (age range 20–85 years), as defined in the 
ATHENA project. Participants were recruited in two 
healthcare centers in Milano (Italy), ASST Santi Paolo 
e Carlo, Division of Nephrology, and IRCCS Galeazzi 
Orthopedic Institute, from June 2012 to December 2013. 
The subjects participating to the study were required 
to be in good health, defined according to individual 
medical history and to routine biochemical, urine and 
instrumental examination (electrocardiogram, ambu-
latory blood pressure monitoring, echocardiography, 
carotid artery and renal ultrasound). Exclusion criteria 
included evidence of cardiovascular or coronary artery 
disease, neoplasm, psychosis and diabetes mellitus. 
The ethic committees of both centres approved the 
study, (Register 441 signed off on 9 June 2011 and Reg-
ister 45-1250-ATHENA signed off on 22 February 2013, 
respectively), in accordance with principles of the Dec-
laration of Helsinki and all participants gave written 
informed consent.
Volunteers underwent a rigorous clinical examination. 
At first visit, we collected baseline anthropometric and 
metabolic measurements and information on diet, per-
sonal medical history and lifestyle. A blood sample was 
also taken for the genetic analysis. We repeated the nutri-
tional interview four times throughout the year in order 
to get seasonal diet variations. Subjects with less than 3 
dietary recall interviews were excluded from the analy-
sis. We then calculated the average annual dietary antho-
cyanins and polyphenols intake for each participant, 
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assuming that this reflects the individual dietary habit. 
We divided participants in two groups according to their 
low or high antioxidant intake, considering anthocyanin 
and polyphenols separately.
Nutritional data collection
Experienced dieticians carried out the dietary assess-
ment through 24 h recall interviews. Food portions were 
defined using a Food Atlas (edited by Scotti-Bassani), 
including 99 tables with photographs. 24  h recall data 
were recorded at least three times in a year, once during 
the first clinical visit and then every 3–4 month.
For data collection and dietary nutrient composition 
estimate we used the Diet Monitoring Solution (DMS) 
software, designed and developed by KOS genetic s.r.l., 
in the context of the Athena project [24]. DMS calculates 
macro- and micro-nutrients composition using composi-
tion tables from the Food Composition Database for Epi-
demiological Studies in Italy (BDA-IEO), integrated with 
tables from the USDA Database for the Flavonoid Con-
tent and from the Phenol Explorer 2.0 Database.
Serum lipids analysis
Determination of HDL, LDL, total cholesterol and tri-
glycerides was carried out on automatic clinical chem-
istry instrumentation (Abbott Architect 8000). Samples 
were analyzed in batches to limit the analytical vari-
ations, after storage at −40  °C for a time not exceeding 
one month. AIP was calculated as the logarithmically 
transformed ratio of triglycerides and HDL concentra-
tion in plasma [25].
Genotyping and imputing
Genomic DNA was extracted from peripheral blood 
using the commercial NucleoSpin Blood Kit by Mach-
erey–Nagel (Macherey–Nagel, Düren, Germany) follow-
ing the manufacturer’s protocol, and stored at −20°. Forty 
hundred and seventy-one samples were genotyped using 
the Illumina HumanCore array (Illumina Inc, San Diego, 
CA, USA) that contains about 300 K highly informative 
genome-wide tag-SNPs including indels and updated 
exome-focused markers. Genotypes were assigned all 
simultaneously using Genome Studio software (version 
V2011.1 genotyping module 1.9.4). Genome-wide impu-
tation was performed using MINIMAC software [26, 27] 
and HapMap CEU haplotypes (release 22) as reference. 
Measured SNPs with call rate  ≥99  % and minor allele 
frequency (MAF)  ≥1  % were included in the dataset. 
Imputed SNPs with low imputation quality (r2 <0.7) were 
not used in the association analysis.
PON1 gene maps to chromosome 7 (chr7:94764924-
94791780). To select SNPs for the analyses, we first 
reviewed all SNPs in this gene, including SNPs mapping 
1  Kb up-stream and down-stream the 5′ and the 3′ of 
the gene. We selected 18 independent tagging SNPs in 
high linkage disequilibrium (r2  ≥0.80) with 18 neigh-
boring SNPs (Table  1). All SNPs complied with Hardy–
Weinberg equilibrium. The 18 selected SNPs covered the 
entire gene and the 3′ and 5′ flanking regions.
Statistical analysis
The genotyped sample underwent quality control in 
accordance with the protocol written by Anderson et al. 
[28]. The degree of recent shared ancestry for a pair of 
individuals was estimated using genome-wide identity by 
descent (IBD) as implemented in PLINK software v1.07 
[29]. We assessed population stratification with principal 
component analysis (PCA) as implemented in SNP and 
Variation Suite v8.x (Golden Helix, Inc., Bozeman http://
www.goldenhelix.com) [30]. We selected the first 10 PCs 
to include as covariates in the linear regression model.
We performed a quantitative trait interaction analysis 
(gene per environment analysis, GxE) testing PON1 SNPs 
association with HDL, LDL, Cholesterol, Triglycerides 
and AIP phenotypes in anthocyanins and polyphenols 
intake environments using PLINK v1.07 [29]. The two 
environmental groups (high and low intake) were defined 
using the two extreme tertiles of anthocyanins and total 
polyphenol intake distributions in order to maximize the 
differences between the two groups. Quantitative traits 
were analysed as residuals, adjusted for sex, age, BMI 
and the first 10 principal components calculated using R 
software [31–35]. For each trait, individuals with miss-
ing data were excluded from the analysis. To correct for 
multiple testing we defined a Bonferroni threshold of 
p =  0.0028. Furthermore, in order to identify the geno-
types that are associated to CVD protection (high HDL, 
low non-HDL cholesterol, triglycerides and AIP) in high 
anthocyanins/polyphenols intake, we performed a multi-
variate regression analysis in high and low environment 
separately using STATA (Stata corp.2015. Stata Statisti-
cal Software: Release 14. College Station, TX: StataCorp 
LP). Analyses were adjusted for BMI, age, gender and 
principal components.
Results
Four hundred and forty-three subjects, 175 males and 
268 females, were fully eligible for the analysis after qual-
ity control of genetic and phenotypic data (Fig. 1).
Among the 500 enrolled participants, 29 subjects with 
less than three dietary recall interviews were excluded, 
leaving 471 subjects for genotyping and downstream 
analysis.
After genotyping, one subject was excluded for low 
call rate (≤0.95) and eight subjects were filtered out for a 
reduced proportion of heterozygosity. We then removed 
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15 related individuals and four genetic outliers after PCA, 
defined as individuals that exceed six standard deviations 
from the whole sample along any of the principal compo-
nents (Additional file 1: Figure S1).
Anthropometric characteristics of the overall sample 
and of each sub-group identified according to antho-
cyanins or polyphenols intake are described in Table  2. 
Anthocyanins intake subgroup included 283 individuals 
while polyphenols subgroup included 295 individuals. 
Subjects with missing biochemical data were excluded 
from each specific analysis (Table 2).
Daily anthocyanins intake ranged between 0 and 
5.98 mg/day in the lower and 25.7 and 614.4 mg/day in 
the higher tertile. Polyphenols intake ranged between 
99.4 and 804.5 mg/day in the lower and between 1288.0 
and 4342.2 mg/day in the higher tertile.
High and low sub-groups were significantly different 
for age in anthocyanins and for sex (Chi squared test 
p  <  0.05) and BMI in polyphenols environment (t test 
p  <  0.05) (Table  2). BMI did not significantly correlate 
with anthocyanins intake (r = −0.05, p =  0.3) whereas 
it weakly correlated with polyphenols intake (r = −0.2, 
p  <  0.0001) (Additional file  2: Figure S2). Interestingly, 
without considering the genetic background, no signifi-
cant difference was observed for HDL, LDL, cholesterol, 
triglycerides and AIP between high and low anthocya-
nins and polyphenols intake. Evaluating the frequency 
of subjects out of the physiological ranges for each lipid 
parameter, we observed that only the percentage of sub-
jects with HDL  <45 in females and  <35 in males is sig-
nificantly higher in the low polyphenols intake sub-group 
compared to the high sub-group (odds ratio 4.4, CI 95 % 
1.6–12.1, p = 0.004 for low intake) (Table 2).
Quantitative trait interaction results for the 18 
selected SNPs in PON1 and CVD biomarkers, consid-
ering anthocyanins and polyphenols intake as envi-
ronment, are presented in Table  3. According to the 
number of analyzed SNPs, the Bonferroni threshold 
is p =  0.0028. A significant p value indicates a differ-
ence in association with the lipid profiles between the 
two environments. The interaction analysis for HDL 
showed that 2 SNPs had a significant p value in inter-
action with anthocyanins (rs854549 flanking the gene 
at the 3′, p =  0.0008 and rs854552, at the 3′ untrans-
lated region (3′ UTR) p = 0.001) and 2 SNPs in inter-
action with polyphenols (rs854571, p  =  0.0021 and 
rs854572 p  =  0.0020, both in the promoter region of 
the gene). A significant interaction model was found 
for rs854551, located at 3′ UTR (p  =  0.0022) in rela-
tion to AIP and anthocyanins and for the intronic 
Table 1 Tagging SNPs analysed in PON1
Bp base pair, MAF minor allele frequency
a Allele frequencies were calculated in the studied population sample
b Position and location were taken from the NCBI build 36 (hg18)
c Tagged SNPs present a r2 >0.80 with analyzed PON1 markers
SNP Alleles  
(minor/major)
MAFa Position (bp) Locationb Tagged SNPsc
rs854549 A/C 0.39 94,764,521 3downstream
rs3735590 A/G 0.05 94,765,431 3downstream rs3917572
rs854551 A/G 0.14 94,765,613 3utr rs854550
rs854552 C/T 0.20 94,765,860 3utr
rs3917567 C/T 0.04 94,768,021 Intronic rs3917556,rs3917527,rs3917551,rs3917548, 
rs3917541,rs3917569,rs2158155
rs854555 A/C 0.33 94,768,327 Intronic
rs3917550 A/G 0.10 94,772,509 Intronic
rs662 C/T 0.30 94,775,382 Coding rs2057681,rs2269829
rs3917538 A/G 0.24 94,775,829 Intronic
rs2074354 A/G 0.13 94,778,523 Intronic rs3917577,rs3917586
rs854560 T/A 0.44 94,784,020 Missense rs705378,rs854561
rs3917498 T/G 0.35 94,784,191 Intronic
rs2074351 A/G 0.30 94,785,735 Intronic
rs2272365 C/A 0.19 94,786,562 Intronic
rs854569 T/G 0.14 94,787,991 Intronic
rs3917477 G/A 0.04 94,789,902 Intronic rs3917476
rs854571 T/C 0.26 94,792,555 5upstream rs854570
rs854572 C/G 0.39 94,792,632 5upstream
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rs3917477 (p =  0.0026) in relation to total cholesterol 
and polyphenols.
Among the significant GxE interactions with HDL, cho-
lesterol and AIP, we then selected the genotypes associ-
ated to CVD protection in the high anthocyanins and 
polyphenols intake. Figure 2 shows the trend of lipid pro-
files across the three genotypes for each significant GxE 
SNP in low or high environment. In particular, in high 
anthocyanins intake, HDL concentration was higher in 
carriers of the major CC genotype for rs854549 (p = 0.001, 
Beta =  4.7) and in the minor CC genotype for rs854552 
(p = 0.001, Beta = 5.6). AIP was lower in minor AA car-
riers for rs854551 (p = 0.034, Beta = −0.07). Considering 
high polyphenols intake, HDL concentration was higher in 
minor TT carriers for rs854571 (p = 0.026, Beta = 3.92) 
and higher in minor CC compared to GG for rs854572 
(p = 0.025, Beta = 3.94). Rs3917477 was not significantly 
associated to cholesterol in high polyphenols intake.
Fig. 1 Participant flow chart
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Table 2 Characteristics of the study sample according to the different environment subgroups (anthocyanins and poly-
phenols intake)
Data are reported as mean ± standard deviation (number of subjects) or percentages. Between-groups comparison of continuous variables was performed using 
one-way analysis of variance (ANOVA); categorical data were compared between groups using the chi2 test or fisher’ exact test
AIP atherogenic index of plasma calculated as [log(triglycerides/HDL)]
* P < 0.05 of the comparison among environment subgroups
Characteristics Total sample Anthocyanins intake Polyphenols intake
High Low High Low
Male (%) 40 41 33 37 49*
Age (years) 51.00 ± 13.96 (443) 53.13 ± 13.83 (141) 47.63 ± 13.57 (142)* 49.60 ± 13.60 (148) 49.54 ± 14.38 (147)
BMI 24.70 ± 4.80 (443) 24.62 ± 4.96 (141) 25.21 ± 5.05 (142) 23.86 ± 4.07 (148) 25.79 ± 5.03 (147)*
Obese subjects, BMI ≥30 (%) 12.9 10.6 18.3 11.5 17
HDL (mg/dl) 54.79 ± 13.30 (428) 54.94 ± 12.85 (141) 54.80 ± 13.27 (142) 55.97 ± 14.45 (143) 53.99 ± 13.70 (143)
<35 mg/dl men, <45 mg/dl  
women (%)
8.6 9.2 12.7 3.5 13.99*
LDL (mg/dl) 125.17 ± 34.51 (429) 128.09 ± 36.77 (141) 124.83 ± 33.27 (142) 121.32 ± 35.26 (143) 126.00 ± 31.90 (144)
≥150 mg/dl (%) 22.1 24.1 21.8 18.8 22.9
Total cholesterol (mg/dl) 201.42 ± 39.28 (430) 203.55 ± 41.54 (141) 200.68 ± 40.64 (142) 197.74 ± 39.46 (143) 203.47 ± 37.98 (145)
>220 mg/dl (%) 30.9 32.4 32.6 29.4 32.4
Triglycerides (mg/dl) 106.32 ± 60.50 (427) 102.56 ± 45.80 (141) 105.69 ± 62.16 (141) 102.64 ± 58.24 (142) 114.62 ± 67.61 (145)
>190 (mg/dl) (%) 8.9 5.7 9.2 9.9 11.1
AIP −0.11 ± 0.26 (421) −0.118 ± 0.24 (141) −0.11 ± 0.26 (141) −0.14 ± 0.26 (142) 0.08 ± 0.27 (143)
Table 3 Results of the interaction analysis between anthocyanin and polyphenols intake and PON1 SNPs on HDL, LDL, 
cholesterol, triglycerides and AIP
Covariates included age, sex, BMI and the first 10 principal components. P values reaching the Bonferroni threshold (p = 0.0028) are highlighted in italics
SNP Anthocyanins intake Polyphenols intake
HDL LDL Cholesterol Triglycerides AIP HDL LDL Cholesterol Triglycerides AIP
rs854549 0.0008 0.3941 0.1031 0.6548 0.1787 0.0998 0.5160 0.2006 0.5240 0.9975
rs3735590 0.3448 0.1405 0.0397 0.0622 0.3134 0.2444 0.0866 0.0303 0.1277 0.2865
rs854551 0.0042 0.6413 0.8251 0.0103 0.0022 0.0206 0.0634 0.0575 0.0064 0.0041
rs854552 0.0010 0.6538 0.3149 0.1498 0.0177 0.0071 0.4599 0.6442 0.1186 0.0493
rs3917567 0.2844 0.3614 0.1339 0.1405 0.5745 0.2103 0.2276 0.0400 0.1382 0.5090
rs854555 0.0412 0.7870 0.5833 0.2299 0.1951 0.4876 0.6883 0.7198 0.7992 0.8506
rs3917550 0.0396 0.7860 0.8563 0.4393 0.2520 0.3543 0.5997 0.3524 0.0470 0.1137
rs662 0.3499 0.4358 0.3243 0.9524 0.8667 0.6203 0.5619 0.6976 0.7735 0.5416
rs3917538 0.4642 0.9174 0.9004 0.4727 0.7861 0.2624 0.8660 0.5450 0.5523 0.7498
rs2074354 0.2774 0.9755 0.6970 0.9028 0.3660 0.0362 0.9619 0.8127 0.1865 0.0592
rs854560 0.0083 0.6339 0.3162 0.4117 0.1807 0.1480 0.9995 0.6245 0.9061 0.5260
rs3917498 0.2024 0.8515 0.7380 0.3965 0.4059 0.7842 0.9222 0.9400 0.9443 0.9068
rs2074351 0.2300 0.5031 0.5218 0.1089 0.1844 0.4547 0.6098 0.2953 0.4237 0.8078
rs2272365 0.6519 0.4859 0.2930 0.2423 0.6737 0.1485 0.5808 0.4599 0.4784 0.3204
rs854569 0.3324 0.4350 0.3155 0.9161 0.7891 0.0071 0.6101 0.0961 0.5367 0.6539
rs3917477 0.9098 0.0364 0.0437 0.4110 0.6409 0.0701 0.0674 0.0026 0.0544 0.4517
rs854571 0.1042 0.3670 0.1272 0.3527 0.9355 0.0021 0.1417 0.0067 0.4772 0.4889
rs854572 0.0087 0.8026 0.2546 0.6123 0.3915 0.0020 0.5219 0.1108 0.8518 0.2163
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Discussion
Within the ATHENA project, we performed a nutrige-
netic observational study to determine whether SNPs 
that describe the genetic variability in PON1 gene can 
influence the response of cardiovascular health bio-
markers to polyphenols and anthocyanins. We collected 
genetic, dietary, environmental, lifestyle data and labora-
tory measurements in 443 healthy Italians. As protective 
biomarkers of cardiovascular health we considered high 
HDL, low total cholesterol, LDL, triglycerides and AIP 
[14, 25].
In our analysis, high and low antioxidant intakes did 
not exert any beneficial effect on the target phenotypes 
if the genetic background related to PON1 gene was not 
considered. These results are in line with previous inter-
ventional studies that showed discordant findings on the 
effect of anthocyanins on common biomarkers of CVD 
[14]. On the contrary, using a nutrigenetic approach, 
we could identify 5 SNPs significant at Bonferroni level 
(rs854549, rs854551, rs854552, rs854571, rs854572) and 
for each SNP we pointed out the genotype with a signifi-
cant cardiovascular protective effect under high antioxi-
dants intake.
In high anthocyanins intake, carriers of the C protec-
tive allele at rs854549 experienced an increase in HDL 
levels of 4.7 mg/dl (p = 0.001) while carriers of the C pro-
tective allele at rs854552 showed an increase of 5.6 mg/
dl (p value 0.001). Considering high polyphenols intake, 
HDL levels were 3.92  mg/dl higher in T carriers for 
rs854571 (p =  0.026) and 3.94  mg/dl higher in C carri-
ers for rs854572 (p = 0.025). These effects are of note if 
we consider that Boes [36] estimated that an increase 
of 1 mg/dl of HDL levels is associated with a 2 and 3 % 
reduction of the risk for coronary artery disease in men 
and women, respectively. AIP was lower in A carriers 
for rs854551, with a decrease of 0.07 (p = 0.034) in high 
anthocyanins intake.
PON1 gene is associated with several human diseases, 
related to oxidative stress including cardiovascular dis-
ease, Parkinson’s disease and cancer [6] and is inversely 
associated to the risk of CVD, particularly to atheroscle-
rosis [37].
PON1 enzyme is tightly associated with HDL particles 
and protects both LDL and HDL from oxidation, a major 
step in the progression of atherosclerosis, the underlying 
pathophysiologic factor for the majority of cardiovascu-
lar diseases [37–39]. HDL contributes to PON1 enzyme 
stabilization, furnishes a hydrophobic environment that 
could be important for PON1 function and is a key player 
in the reverse cholesterol transport, which shuttles cho-
lesterol from peripheral cells (e.g. macrophages) to the 
liver or other tissues.
As lifestyle determinants such as smoking, alcohol 
intake and exogenous or endogenous oxidants can modify 
Fig. 2 Phenotypes distribution relative to genotypes at best SNPs according to anthocyanins and polyphenols intakes. rs854549 (a), rs854551 (b), 
rs854552 (c), rs3917477 (d), rs854571 (e) and rs854572 (f). Y axis reports the residuals calculated for each phenotype (HDL, AIP and cholesterol) 
adjusted for age, sex, BMI and the first ten principal components. The bars summarize the distribution as mean and standard errors. For each bar, the 
numbers of individuals per genotype are indicated. PGxE denotes the SNP x environment interaction analysis comparing high and low intake both 
for anthocyanins (a–c) and polyphenols (d–f). P indicates the multivariate linear regression analysis comparing genotypes in each environment sub-
group (low/high); Beta coefficients refer to minor alleles
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PON1 levels and activity, several strategies were used to 
test if antioxidant supplementation, including polyphe-
nols and anthocyanins, could improve PON1 function. It 
has been demonstrated that anthocyanins and polyphe-
nols promote antioxidant activity and cholesterol efflux 
capacity of HDL. They also enhance PON1 stabilization, 
its association with HDL and catalytic activity [15, 16, 40].
Rs854549, that we found associated to HDL in inter-
action with anthocyanins intake, is a 3′ flanking variant, 
repeatedly reported as tagger SNP for PON1 and as mod-
ulator of PON1 activities [41, 42].
Huen et al. reported rs854551 and rs854552, both map-
ping at the 3′ UTR of the gene, as significantly associated 
to paraoxonase activity of PON1 in a study on Mexican 
Newborn and Mothers [42].
Rs854571 and rs854572 map in the promoter region 
of PON1 gene and have been independently reported to 
produce an approximatively two-fold change in PON1 
expression levels in human hepatoma cell line HepG2 [38, 
43]. Leviev [43] reported a significant increase in activ-
ity of PON1 promoter related to the T allele of rs854571, 
the same allele that we found associated to higher level of 
HDL in high anthocyanins intake. Brophy [38] showed a 
significant increase in activity of PON1 promoter related 
to the G allele of rs854572, that in our sample was asso-
ciated to lower HDL levels in high anthocyanins intake. 
A recent genome-wide association analysis demonstrated 
that PON1 polymorphisms are strongly associated to 
PON1 function, and especially rs854572 is the best pre-
dictor of arylesterase activity [20].
On the contrary, associations between PON1 SNPs 
and lipid profiles have been mostly controversial [21–23, 
36, 44–46]. Nus et al. [23] evaluated the effect of walnut 
enriched meat consumption on lipid profile, in subjects at 
increased risk of CVD, according to rs662 and rs854560 
genotypes. They observed that rs662 TT carriers had 
lower HDL, LDL and triglycerides levels compared to 
C carriers and that the difference increased if the SNPs 
were considered in interaction (rs662 TT  +  rs854560 
TT  +  AT versus the other genotypes). However, the 
lipid profile did not differ between rs662 and rs854560 
after consumption of either walnut enriched or con-
trol meat diet. De Souza et  al. in a pharmacogenom-
ics study on statin response in Brazilians, found that T 
allele carriers of rs854560 reached their HDL lipid target 
(HDL >1.55 mmol/L) more often than patients who were 
homozygous AA. Rios et al. [44]. showed rs662 as associ-
ated to triglycerides and HDL levels in male Caucasian-
Brazilians. Van Himbergen et al. [45] found that genetic 
variants in PON1 associated with high levels and activity 
of the enzyme, were also associated with higher HDL lev-
els. That study, however, was performed in patients with 
familial hypercholesterolemia with a high prevalence of 
atherosclerosis in the population. Van Aalst-Cohen et al. 
[46] in a familial hypercholesterolemia study and Blat-
ter Garin et al. [21] in a case control study on coronary 
artery disease could not find any association between the 
two coding polymorphisms rs854560 and rs662 and HDL 
level. In our study, rs854560 was significantly associated 
to HDL in interaction with anthocyanins (p = 0.0083) but 
the significance was not confirmed after correction for 
multiple testing. There was a tendency for TT homozy-
gous to higher HDL levels in high anthocyanins intake. 
Rs662 was not associated to any of the phenotype tested.
Though a limitation of our study could be the small sam-
ple size, its strength is an accurately phenotyped cohort 
that includes subjects with well-established long-term 
dietary habits regarding antioxidant intake. To address 
bias due to self-reported data from the nutritional inter-
view, trained dieticians conducted the 24 h dietary recall 
using pictures (i.e. validated Food Atlas) to help peo-
ple identifying food portions. In addition, as seasonality 
affects anthocyanins levels that are higher in summer and 
lower in winter, we repeated the 24 h recall interview at 
least three times a year and used the average yearly intake 
for all the analyses [47, 48]. This has increased the preci-
sion in evaluating the chronic effect of the diet on lipid 
profile. Moreover, the DMS software, integrating different 
databases, returns a detailed estimate of the anthocyanins 
and polyphenols content for all the recorded foods. A val-
idation on an independent sample would allow confirm-
ing causality of the SNPs identified in the present study.
Conclusions
This nutrigenetic study highlights the role of PON1 as 
susceptibility gene for cardiovascular health under high 
antioxidant intake. We identified protective genotypes in 
4 independent polymorphisms, presenting a significant 
association with increased HDL level under high poly-
phenols and anthocyanins intake. The identified alleles 
could be used to stratify subjects who can benefit from 
high antioxidant consumption to improve their HDL 
levels.
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